Filing Details

Accession Number:
0001213900-25-015704
Form Type:
13G Filing
Publication Date:
2025-02-19 19:00:00
Filed By:
Nirland Limited
Company:
Conduit Pharmaceuticals Inc.
Filing Date:
2025-02-20
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Beneficially Owned Number of Shares Beneficially Owned Number of Aggregate Shares Percent of Class
Nirland Limited 0 0 0%
Stockton Limited 0 0 0%
The Rowland Master Trust 0 0 0.00%
Dovet Limited 0 0 0%
Filing





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G




SCHEDULE 13G




SCHEDULE 13G




SCHEDULE 13G



Comment for Type of Reporting Person:  (1) Nirland Limited is wholly owned by Stockton Limited, a company registered in Guernsey ("Stockton Limited"), which is wholly owned by The Rowland Master Trust, a Guernsey trust ("The Rowland Master Trust"). Dovet Limited, a company registered in Guernsey ("Dovet Limited"), is the sole trustee of The Rowland Master Trust. By virtue of these relationships, each of Stockton Limited, The Rowland Master Trust and Dovet Limited may be deemed to share beneficial ownership of the securities held of record by Nirland Limited.


SCHEDULE 13G


 
Nirland Limited
 
Signature:/s/ David Rowland
Name/Title:David Rowland/Director
Date:02/20/2025
 
Stockton Limited
 
Signature:/s/ David Rowland
Name/Title:David Rowland/Director
Date:02/20/2025
 
The Rowland Master Trust
 
Signature:/s/ Barclay Rowland
Name/Title:Barclay Rowland/Director
Date:02/20/2025
 
Dovet Limited
 
Signature:/s/ Barclay Rowland
Name/Title:Barclay Rowland/Director
Date:02/20/2025